 |
|
Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs
A Population-Based Case-Control Study
Søren P. Johnsen, MD, PhD;
Heidi Larsson, MSc;
Robert E. Tarone, PhD;
Joseph K. McLaughlin, PhD;
Bente Nørgård, MD, PhD;
Søren Friis, MD;
Henrik T. Sørensen, DMSc
Arch Intern Med. 2005;165:978-984.
Background It remains uncertain if the excess cardiovascular risk of rofecoxib and celecoxib reported in clinical trials is present in routine practice and whether the use of other nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) also carries an increased cardiovascular risk. We performed a population-based case-control study to examine the risk of myocardial infarction (MI) among users of various categories of nonaspirin NSAIDs.
Methods Using data from hospital discharge registries in the counties of North Jutland, Viborg, and Aarhus, Denmark, and the Danish Civil Registration System, we identified 10 280 cases of first-time hospitalization for MI and 102 797 sex- and age-matched non-MI population controls. All prescriptions for nonaspirin NSAIDs filled before the date of admission for MI were identified using population-based prescription databases. Relative risk estimates for MI were adjusted for a history of cardiovascular disease, hypertension, diabetes mellitus, chronic bronchitis or emphysema, alcoholism, liver cirrhosis, upper gastrointestinal bleeding, rheumatoid arthritis, systemic lupus erythematosus and the use of high-dose aspirin, platelet inhibitors, insulin or oral hypoglycemic drugs, antihypertensive drugs, lipid-lowering drugs, oral anticoagulants, nitrates, penicillamine, gold, oral glucocorticocoids, and hormone therapy before the date of admission for MI.
Results Current users of rofecoxib had an elevated risk estimate for hospitalization for MI compared with nonusers of any category of nonaspirin NSAIDs (adjusted relative risk [ARR], 1.80; 95% confidence interval [CI], 1.47-2.21). Increased risk estimates were also found among current users of celecoxib (ARR, 1.25; 95% CI, 0.97-1.62), other cyclooxygenase-2 selective inhibitors (ARR, 1.45; 95% CI, 1.09-1.93), naproxen (ARR, 1.50; 95% CI, 0.99-2.29), and other conventional nonaspirin NSAIDs (ARR, 1.68; 95% CI, 1.52-1.85). The highest ARRs were found among new users of all examined drug categories.
Conclusions Current and new users of all classes of nonaspirin NSAIDs had elevated relative risk estimates for MI. Although the increased risk estimates may partly reflect unmeasured bias, they indicate the need for further examination of the cardiovascular safety of all nonaspirin NSAIDs.
Author Affiliations: Department of Clinical Epidemiology, Aarhus Hospital, Aarhus University Hospital, Aarhus, Denmark (Drs Johnsen, Nørgård, and Sørensen and Ms Larsson); Center of Cardiovascular Research, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark (Dr Johnsen); International Epidemiology Institute, Rockville, Md (Drs Tarone and McLaughlin); Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, Tenn (Drs Tarone and McLaughlin); and Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark (Dr Friis).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease
Hennekens and Borzak
J CARDIOVASC PHARMACOL THER 2008;13:41-50.
ABSTRACT
Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs
Joshi et al.
Anesth. Analg. 2007;105:1793-1804.
ABSTRACT
| FULL TEXT
Are We Ignoring the Elephant in the Room?
Jindeel
Arch Intern Med 2007;167:2263-2264.
FULL TEXT
Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials
Scott et al.
Ann Rheum Dis 2007;66:1296-1304.
ABSTRACT
| FULL TEXT
Evolution of medical treatment for endometriosis: back to the roots?
Wieser et al.
Hum Reprod Update 2007;13:487-499.
ABSTRACT
| FULL TEXT
Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer
Kerr et al.
NEJM 2007;357:360-369.
ABSTRACT
| FULL TEXT
Approach to managing musculoskeletal pain: Acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?
Hunt et al.
cfp 2007;53:1177-1184.
ABSTRACT
| FULL TEXT
Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe?
Waksman et al.
The Annals of Pharmacotherapy 2007;41:1163-1173.
ABSTRACT
| FULL TEXT
An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs
Ong et al.
Clin Med Res 2007;5:19-34.
ABSTRACT
| FULL TEXT
Exercise can be pyrogenic in humans
Bradford et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007;292:R143-R149.
ABSTRACT
| FULL TEXT
Non-steroidal anti-inflammatory drugs--changes in prescribing may be warranted
Madhok et al.
Rheumatology (Oxford) 2006;45:1458-1460.
FULL TEXT
Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2
McGettigan and Henry
JAMA 2006;296:1633-1644.
ABSTRACT
| FULL TEXT
Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.
Chaiamnuay et al.
Am J Health Syst Pharm 2006;63:1837-1851.
ABSTRACT
| FULL TEXT
Use of Non-Aspirin Nonsteroidal Antiinflammatory Drugs and the Risk of Cardiovascular Events
Cheng
The Annals of Pharmacotherapy 2006;40:1785-1796.
ABSTRACT
| FULL TEXT
NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland
Helin-Salmivaara et al.
Eur Heart J 2006;27:1657-1663.
ABSTRACT
| FULL TEXT
Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction
Gislason et al.
Circulation 2006;113:2906-2913.
ABSTRACT
| FULL TEXT
Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors
Levesque et al.
CMAJ 2006;174:1563-1569.
ABSTRACT
| FULL TEXT
Use of First- and Second-Generation Cyclooxygenase-2-Selective Nonsteroidal Antiinflammatory Drugs and Risk of Acute Myocardial Infarction
Andersohn et al.
Circulation 2006;113:1950-1957.
ABSTRACT
| FULL TEXT
Understanding the NSAID related risk of vascular events.
Vonkeman et al.
BMJ 2006;332:895-898.
FULL TEXT
Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events
Chan et al.
Circulation 2006;113:1578-1587.
ABSTRACT
| FULL TEXT
Update on Cyclooxygenase-2 Inhibitors
Harris and Breyer
CJASN 2006;1:236-245.
ABSTRACT
| FULL TEXT
COX-2 chronology
Hawkey
Gut 2005;54:1509-1514.
ABSTRACT
| FULL TEXT
To the Heart of the Matter: Coxibs, Smoking, and Cardiovascular Risk
Hermann et al.
Circulation 2005;112:941-945.
FULL TEXT
Cyclooxygenase Inhibition and Cardiovascular Risk
Antman et al.
Circulation 2005;112:759-770.
FULL TEXT
|
